{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/polymyalgia-rheumatica/background-information/prevalence/","result":{"pageContext":{"chapter":{"id":"40912c6f-7953-5028-8087-bfe412fe8144","slug":"prevalence","fullItemName":"Prevalence","depth":2,"htmlHeader":"<!-- begin field 82de043a-cbfe-4c5f-a1e2-88021a42f1b2 --><h2>How common is it?</h2><!-- end field 82de043a-cbfe-4c5f-a1e2-88021a42f1b2 -->","summary":"","htmlStringContent":"<!-- begin item b6685c47-7c67-4d96-90cd-fe43e7a3c4c6 --><!-- begin field 6fbe2528-47ab-42f5-a537-5860e5926943 --><ul><li><strong>Polymyalgia rheumatica (PMR) is the most common inflammatory rheumatic disease in older people</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/references/\">Matteson, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/references/\">Partington, 2018</a>], and one of the most common indications for long-term corticosteroid treatment in the UK, accounting for 22% of prescriptions [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/references/\">Dasgupta et al, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/references/\">Ameer, 2014</a>].</li><li>A large population-based study (n = 5,364,005) assessed the incidence, prevalence, and treatment burden of PMR in the UK over two decades (1990–2016) in people aged over 40 years [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/references/\">Partington, 2018</a>]:<ul><li>During the period, 42,125 people had an incident diagnosis of PMR. The overall incidence rate of PMR was 95.9 per 100,000, and the incidence was highest in women, older age groups, and those living in the South of England. </li><li>The prevalence of PMR in 2015 was 0.85%.</li></ul></li><li>A study of primary care computer records assessed the prevalence of PMR and giant cell arteritis (GCA) in a GP practice in Norfolk by reviewing clinical data for diagnoses of both conditions. This was supplemented by postal survey (to identify potentially undiagnosed cases within the practice population) and subsequent clinical review (for those screening positive for potential diagnoses of PMR and GCA [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polymyalgia-rheumatica/references/\">Yates, 2016</a>]. <ul><li>From the GP case records (n = 5159), 117 people had a recorded diagnosis of PMR and 21 people had GCA.</li><li>From the population survey (n = 4728), no new cases of PMR and GCA were identified among 2227 completed questionnaires returned.</li><li>The resulting cumulative prevalence estimate in those aged 55 years and older meeting 5 published criteria sets for PMR ranged from 0.91–1.53%.</li><li>The prevalence of both conditions was higher in women than in men, and in older age groups.</li></ul></li></ul><!-- end field 6fbe2528-47ab-42f5-a537-5860e5926943 --><!-- end item b6685c47-7c67-4d96-90cd-fe43e7a3c4c6 -->","topic":{"id":"ce8b01ca-f53a-55a3-8d34-3f1c4627fe6a","topicId":"ad21d80a-1ea5-4ead-b50d-c84a90f81dfd","topicName":"Polymyalgia rheumatica","slug":"polymyalgia-rheumatica","lastRevised":"Last revised in January 2019","chapters":[{"id":"1422f739-c18d-5e1e-a304-97c38c53326d","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"16d2834f-dff7-5cdb-a7f4-58e78255d2d2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"e0b8f18b-6f9c-5652-83d0-dafbd8f023f1","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"45868673-afab-57d2-a5d7-8e82c7a6a1d6","slug":"changes","fullItemName":"Changes"},{"id":"5b1ee373-bd86-5e9d-812b-4832f6246571","slug":"update","fullItemName":"Update"}]},{"id":"27cf37e3-9a75-54bf-b40c-a9a5d3ab8774","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f98bc06e-32e0-5d1b-955b-704d835dadfc","slug":"goals","fullItemName":"Goals"},{"id":"de16a1ee-5b79-561d-aa33-007310d41806","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"27fd23e5-8ea0-5fc4-a238-92290ecf2d96","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"07ae7b26-b61c-5b1d-a11a-2e2f8831b2b4","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"40fc7a60-984c-568d-bca4-9c74b0dd12ad","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"51474ce0-d36a-55b4-be78-dce9cacb0267","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"05f711b1-05e6-5832-a014-0d48622761aa","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"2ff5c538-1fb7-5d1b-bd20-0b559053d445","slug":"definition","fullItemName":"Definition"},{"id":"222a21f0-7691-5217-92ac-d0b454809378","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"40912c6f-7953-5028-8087-bfe412fe8144","slug":"prevalence","fullItemName":"Prevalence"},{"id":"0c6caaf8-c9e3-5154-ad85-0639ce885933","slug":"complications","fullItemName":"Complications"},{"id":"7dad7582-0879-5b1d-a434-a7385c6bf62a","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"f0e2a168-bba6-5e5e-9290-792a786adf37","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"18cd5747-18a3-56ba-bc8b-4426d03187a4","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"d17676a0-b0c6-5edc-8a36-71ff56514267","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"5928ae5b-d1b2-5880-b5d0-520d3eefbbb3","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"42122189-74ea-5630-87b7-23f6266addc0","fullItemName":"Management","slug":"management","subChapters":[{"id":"047c46a8-6c2e-538d-b303-898bc35b204c","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"ad839214-35b0-58d1-b8ec-1d66a6be3eb0","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"fa86dcab-a820-5a5f-a76d-e237364c1e7b","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"caac4d3d-be17-58bd-b762-bb897b659611","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"7cfd6eb7-5b49-52a2-aa31-f8bf0144547c","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"7e0cae2d-7716-577b-8a6f-249f600698b5","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e8a07059-cd02-573a-819c-26383cacb522","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"d99f4de4-aa27-5079-811c-923190c5046a","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a29113d9-3ec2-598e-9d77-05509c1df517","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"05f711b1-05e6-5832-a014-0d48622761aa","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}